Hormonal
Tirzepatide (a dual GIP/GLP-1 receptor agonist) administered weekly via subcutaneous injection significantly reduces HbA1c and body weight in adults with type 2 diabetes compared to placebo, semaglutide, and insulin.
If you have type 2 diabetes, a once-weekly injection called tirzepatide can significantly lower your blood sugar and help you lose weight, often more effectively than insulin or other common diabetes medications. While you might experience some stomach upset initially, it usually gets better, and the benefits for your heart and liver are also promising.
SURPASS-1 investigated tirzepatide monotherapy... HbA1c reductions were 21mmol/mol (1.9%), 21mmol/mol (1.9%) and 23mmol/mol (2%) with 5mg, 10mg and 15mg tirzepatide respectively. A dose dependent weight loss of 7–9.2kg was seen.
Why this rating
Based on multiple phase 3 double-blind randomized controlled trials (SURPASS series).
Source
Promising outcomes from latest landmark diabetes trials: tirzepatide and finerenone in the spotlight
Lakshmi Sankaran et al. · Practical Diabetes · 2023
DOI 10.1002/pdi.2432
More from this paper
- Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces cardiovascular and renal risks in patients with type 2 diabetes and chronic kidney disease.Strong
- Semaglutide (2.4mg weekly) leads to significant weight loss in adults with obesity or overweight, and maintaining treatment prevents weight regain.Strong
- Incretin-based treatments (semaglutide, dulaglutide) are effective and safe in adolescents with obesity or type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →